Gaorong Capital
VC Fund
Wangjing, China
Gaorong Capital is a venture capital firm that focuses on early and growth stage investments in TMT, including AI and frontier technologies.
- Total investments:
- 370
- Last investment:
- Lead investor:
- 29%
- Fund size:
- $185M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Gaorong Capital invests in
Stages Gaorong Capital invests in
Countries Gaorong Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 9 contacts → | |||
Round size
- Seed
- $2.8M–$100M
- Series A
- $1.6M–$75M
- Series B
- $14M–$110M
Investment Focus
Industry
- Artificial Intelligence 39 (11%)
- Information Technology 31 (8%)
- Software 30 (8%)
- E-Commerce 30 (8%)
- Biotechnology 29 (8%)
Stage
- Series A 125 (34%)
- Series B 73 (20%)
- Seed 41 (11%)
- Angel 38 (10%)
- Series C 32 (9%)
Country
- China 218 (59%)
- United States 14 (4%)
- Singapore 6 (2%)
- Hong Kong 5 (1%)
- Japan 1 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Bin Yue
Founding Partner
|
Founding Partner | Total investments: 6 | Find email | |
|
Han Rui
partner
|
partner | Total investments: 3 | Find email | |
|
Hu Shuo
partner
|
partner | Total investments: 3 | Find email | |
John Renk
Founding Partner
|
Founding Partner | Total investments: 10 | Find email | |
|
Kevin Yang
Partner
|
Partner | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Sequence Technology
|
Sequence Technology emphasizes in the production of polymer materials used in the semiconductor manufacturing process. | $14.9M / Series B / Sep 17, 2026 | |
| Anew Labs is an AI drug discovery company that combines generative models with experimental science. | $290M / Series A / Sep 16, 2026 | ||
| Inno Pharmaceutical Technology specializes in research on the pathogenesis of atherosclerosis. The company focuses on the development of targeted nanoliposomes, targeting molecules with independent intellectual property rights, and currently focuses on the plaque reversal treatment of atherosclerosis. | $119.2M / Series D / Sep 09, 2026 | ||
| Moonwalk Biosciences is a genomic medicine startup that aims to provide a new class of precision epigenetic therapeutics. The company is working on the development of a profiling and engineering technology platform that, with the help of advanced artificial intelligence prediction, provides a comprehensive view of the epigenome in health anddisease, allowing healthcare providers to take a fresh look at how therapies are discovered and developed. | $70M / Series B / Sep 08, 2026 | ||
| Tianji develops industrial robotics and intelligent system solutions focused on improving automation in manufacturing environments. The company designs and integrates robot-based systems, including industrial robots, automation equipment, and intelligent production line solutions. It applies technologies such as machine vision, motion control, andedge computing to support tasks like production automation, quality inspection, and logistics handling. Its solutions are used across industries such as manufacturing, healthcare, and new energy to help optimize operational processes and improve safety. | Series B / Sep 08, 2026 | ||
ALLYRNA Pharmaceuticals
|
ALLYRNA, an innovative small molecule drug developer focused on first-in-class drug development, has established a unique platform for radiotherapy and immunotherapy sensitizers. | $100M / Seed / Aug 26, 2026 | |
| Xpeng Robotics a Shenzen, China-based affiliate of XPeng Inc. and a key part of its mobility ecosystem dedicated to creating smart robots, | $900M / Series A / Aug 24, 2026 | ||
|
Weiling Medical
|
Wiling Medical offers extensive knowledge of the principles and clinical uses of implantable brain-computer interfaces as well as extensive experience in basic research engineering practise, and clinical care. | Venture - Series Unknown / Aug 17, 2026 | |
| Pragmatik Labs build digital agents that transform knowledge work and physical agents that bring intelligence into real environments, starting from systems that reason, use tools, learn from feedback, and coordinate action. | $220M / Angel / Aug 12, 2026 | ||
| Genta Kyushu Bio is a cutting edge biotechnology company specializing in the development of precision neuro circuit therapies for central nervous system and ophthalmic diseases. The firm leverages its high throughput screening and drug development platforms to advance innovative treatments utilizing chemogenetics, optogenetics, and gene therapies. | $14.8M / Series A / Jul 30, 2026 | ||
| See all 370 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Gaorong Capital invest in?
Gaorong Capital invests primarily in Artificial Intelligence, Information Technology and Software startups, most often at Series A and Series B stage. Most of the 370 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Gaorong Capital's check size?
Gaorong Capital typically joins rounds of $2.8M–$100M at Seed, $1.6M–$75M at Series A and $14M–$110M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Gaorong Capital participates in.
How do I contact Gaorong Capital?
Public channels for Gaorong Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Gaorong Capital?
The team at Gaorong Capital includes Bin Yue (Founding Partner), Han Rui (partner) and Hu Shuo (partner), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
